Try
Ginkgo Bioworks Holdings Inc. Class A Common Stock
DNAUnited States
5 filed reports · 375 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 1,030 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 1,016 | Dec 2025 |
Financial data
375 concepts · 2,046 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial360 concepts · 1,863 facts · Dec 2023 to Jun 2026
- Cash and cash equivalents at carrying value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Restricted cash13 · Dec 2023 to Jun 2026
- Restricted cash current13 · Dec 2023 to Jun 2026
- Restricted cash equivalents noncurrent13 · Dec 2023 to Jun 2026
- Stockholders equity (US GAAP)13 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Amortization of intangible assets12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Employer payroll taxes12 · Dec 2023 to Jun 2026
- Equity securities without readily determinable fair value impairment loss annual amount12 · Dec 2023 to Jun 2026
- Gain loss on investments12 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
- Other operating income expense net12 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Restructuring costs and asset impairment charges12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Capital expenditures incurred but not yet paid11 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect11 · Dec 2023 to Jun 2026
- Depreciation and amortization11 · Dec 2023 to Jun 2026
Segment12 concepts · 136 facts · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)23 · Dec 2023 to Jun 2026
- Revenue23 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)22 · Dec 2023 to Jun 2026
- Research and development expense22 · Dec 2023 to Jun 2026
- Operating income loss18 · Dec 2023 to Dec 2025
- Business combination acquisition related costs4 · Mar 2025 to Jun 2026
- Depreciation and amortization4 · Mar 2025 to Jun 2026
- Employee benefits and share based compensation4 · Mar 2025 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest4 · Mar 2025 to Jun 2026
- Lease cost4 · Mar 2025 to Jun 2026
- Other nonoperating income expense4 · Mar 2025 to Jun 2026
- Restructuring costs and asset impairment charges4 · Mar 2025 to Jun 2026
Product3 concepts · 47 facts · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)17 · Dec 2023 to Dec 2025
- Revenue17 · Dec 2023 to Dec 2025
- Revenue from Contract with Customer, Excluding Assessed Tax, Noncash13 · Dec 2023 to Jun 2026
Segments
183 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments3 members · 136 facts
- Biosecurity47 · Dec 2023 to Dec 2025
- Cell Engineering45 · Dec 2023 to Dec 2025
- Reportable44 · Mar 2025 to Jun 2026
Product or service7 members · 47 facts
- Cell Engineering13 · Dec 2023 to Jun 2026
- Service8 · Dec 2023 to Dec 2025
- Cell Engineering Revenue7 · Dec 2023 to Dec 2025
- Biosecurity6 · Jun 2024 to Sep 2025
- Product6 · Dec 2023 to Dec 2025
- Product And Service Other5 · Dec 2023 to Dec 2025
- Other Revenue2 · Sep 2024 to Sep 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
- FY2026 Q1May 7, 2026
- FY2025 Q4Feb 27, 2026
- FY2025 Q3Nov 6, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.